Reply to R.J. Buckanovich et al

Affiliations

Comment

Sara Bouberhan et al. J Clin Oncol. 2019.

. 2019 Oct 10;37(29):2708-2709.

doi: 10.1200/JCO.19.01670. Epub 2019 Aug 26.

¹ Sara Bouberhan, MD; Meghan Shea, MD; and Stephen A. Cannistra, MD, Beth Israel Deaconess Medical Center, Boston, MA.

No abstract available

Comment on

Advanced Epithelial Ovarian Cancer: Do More Options Mean Greater Benefits?
Bouberhan S, Shea M, Cannistra SA. Bouberhan S, et al. J Clin Oncol. 2019 Jun 1;37(16):1359-1364. doi: 10.1200/JCO.19.00500. Epub 2019 Apr 19. J Clin Oncol. 2019. PMID: 31002579
No Role for Maintenance Bevacizumab for Up-Front Stage IIIc (R0) Ovarian Cancer.
Buckanovich RJ, Rustin G, Uppal S, Olawaiye AB, Kelley JL, Berger JL, Landen CN. Buckanovich RJ, et al. J Clin Oncol. 2019 Oct 10;37(29):2707-2708. doi: 10.1200/JCO.19.01650. Epub 2019 Aug 26. J Clin Oncol. 2019. PMID: 31449471 No abstract available.